Treatment of hepatitis b: A concise review

Clinical and Translational Gastroenterology

Volumn 7, Issue 9, 2016, Pages E190-

  Rajbhandari, Ruma ^a,b   Chung, Raymond T ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ANTIVIRUS AGENT; ARC 520; AZATHIOPRINE; BULEVIRTIDE; CYCLOSPORINE; EMTRICITABINE; ENTECAVIR; EZETIMIBE; GLS 4; GLUCOCORTICOID; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; METHOTREXATE; NVR 3 778; PEGINTERFERON ALPHA2A; PHENYLPROPENAMIDE DERIVATIVE; PLACEBO; REP 9AC; RITUXIMAB; SIRTINOL; SMALL INTERFERING RNA; TELBIVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS DNA;

ACUTE HEPATITIS B; ANOREXIA; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; CHRONIC HEPATITIS B; COMPENSATED LIVER CIRRHOSIS; COUGHING; DECOMPENSATED LIVER CIRRHOSIS; DRUG MEGADOSE; DRUG TARGETING; FANCONI RENOTUBULAR SYNDROME; FATIGUE; FLU LIKE SYNDROME; HAIR LOSS; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY FAILURE; KIDNEY TUBULE ACIDOSIS; LIFE CYCLE; NONHUMAN; PREGNANCY; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VIRAL GENOMICS; VIRUS CAPSID; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION;

EID: 85085085894     PISSN: 2155384X     EISSN: None     Source Type: Journal    
DOI: 10.1038/ctg.2016.46     Document Type: Review

References (94)

1. Ly KN, Xing J, Monina Klevens R et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 20Ann Intern Med 2012; 156: 271 278.
2. Giannini EG, Torre F, Basso M et al. A significant proportion of patients with chronic hepatitis B who are candidates for antiviral treatment are untreated: A region-wide survey in Italy. J Clin Gastroenterol 2009; 43: 1001 1007.
3. Zhang S, Garcia RT, Ristau JT et al. Undertreatment of Asian chronic hepatitis B patients on the basis of standard guidelines: A community-based study. Dig Dis Sci 2012; 57: 1373 1383.
4. Jung CW, Tan J, Tan N et al. Evidence for the insufficient evaluation and undertreatment of chronic hepatitis B infection in a predominantly low-income and immigrant population. J Gastroenterol Hepatol 2010; 25: 369 375.
5. Cohen C, Holmberg SD, McMahon BJ et al. Is chronic hepatitis B being undertreated in the United States? J Viral Hepat 2011; 18: 377 383.
6. Lok ASF, McMahon BJ. Chronic hepatitis B: update 20Hepatology 2009; 50: 661 662.
7. European Association for the Study of the LiverEASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167 185.
8. Yapali S, Talaat N, Lok AS. Management of hepatitis B: our practice and how it relates to the guidelines. Clin Gastroenterol Hepatol 2014; 12: 16 26.
9. Liaw YF, Kao JH, Piratvisuth T et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update. Hepatol Int 2012; 6: 531 561.
10. Urban S, Schulze A, Dandri M et al. The replication cycle of hepatitis B virus. J Hepatol 2010; 52: 282 284.
11. Yan H, Zhong G, Xu G et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 2012; 1: e00049.
12. Ni Y, Lempp FA, Mehrle S et al. Hepatitis B and D viruses exploit sodium taurocholate co-Transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 2014; 146: 1070 1083.
13. Tong S, Li J. Identification of NTCP as an HBV receptor: The beginning of the end or the end of the beginning? Gastroenterology 2014; 146: 902 905.
14. Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: Towards restoration of immune control of viral infection. Postgrad Med J 2013; 89: 294 304.
15. Lai M, Hyatt BJ, Nasser I et al. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007; 47: 760 767.
16. Shim JH, Lee HC, Kim KM et al. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010; 52: 176 182.
17. Liaw Y-F, Sheen I-S, Lee C-M et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 53: 62 72.
18. Lian J-S, Zeng L-Y, Chen J-Y et al. De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis. World J Gastroenterol 2013; 19: 6278 6283.
19. Köklö S, Tuna Y, Göl?en MT et al. Long-Term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin Gastroenterol Hepatol 2013; 11: 88 94.
20. Milazzo F, Vigevani GM, Almaviva M et al. Attempted treatment of fulminant viral hepatitis with human fibroblast interferon. Infection 1985; 13: 130 133.
21. Sánchez-Tapias JM, Mas A, Costa J et al. Recombinant alpha 2c-interferon therapy in fulminant viral hepatitis. J Hepatol 1987; 5: 205 210.
22. Kundu SS, Kundu AK, Pal NK. Interferon-Alpha in the treatment of acute prolonged hepatitis B virus infection. J Assoc Physicians India 2000; 48: 671 673.
23. Tassopoulos NC, Koutelou MG, Polychronaki H et al. Recombinant interferon-Alpha therapy for acute hepatitis B: A randomized, double-blind, placebo-controlled trial. J Viral Hepat 1997; 4: 387 394.
24. Yu J-W, Sun L-J, Zhao Y-H et al. The study of efficacy of lamivudine in patients with severe acute hepatitis B. Dig Dis Sci 2010; 55: 775 783.
25. Tillmann HL, Hadem J, Leifeld L et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006; 13: 256 263.
26. Schmilovitz-Weiss H, Ben-Ari Z, Sikuler E et al. Lamivudine treatment for acute severe hepatitis B: A Pilot study. Liver Int 2004; 24: 547 551.
27. Kondili LA, Osman H, Mutimer D. The use of lamivudine for patients with acute hepatitis B (a series of cases). J Viral Hepatitis 2004; 11: 427 431.
28. Hasan F, Owaid SAM. Lamivudine monotherapy for severe acute hepatitis B. J Hepatol 2005; 42: 178 179.
29. Sanchez MJ, Buti M, Homs M et al. Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab. J Hepatol 2009; 51: 1091 1096.
30. Brost S, Schnitzler P, Stremmel W et al. Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients. World J Gastroenterol 2010; 16: 5447 5451.
31. Rago A, Lichtner M, Mecarocci S et al. Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for HBV reactivation following a rituximab-based regimen. Antivir Ther 2010; 15: 929 932.
32. Watanabe M, Shibuya A, Takada J et al. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: A review of 16 patients. Eur J Intern Med 2010; 21: 333 337.
33. Garg H, Sarin SK, Kumar M, Garg V et al. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology 2011; 53: 774 780.
34. Milazzo L, Corbellino M, Foschi A et al. Late onset of hepatitis B virus reactivation following hematopoietic stem cell transplantation: successful treatment with combined entecavir plus tenofovir therapy. Transpl Infect Dis 2012; 14: 95 98.
35. Wong VW-S, Wong GL-H, Yiu KK-L et al. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J Hepatol 2011; 54: 236 242.
36. Chen C-H, Lin C-L, Hu T-H et al. Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation. J Hepatol 2014; 60: 1127 1134.
37. Zhang Y, Hu X-Y, Zhong S et al. Entecavir vs lamivudine therapy for naïve patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. World J Gastroenterol 2014; 20: 4745 4752.
38. Gupta S, Govindarajan S, Fong TL et al. Spontaneous reactivation in chronic hepatitis B: patterns and natural history. J Clin Gastroenterol 1990; 12: 562 568.
39. Kim SJ, Hsu C, Song Y-Q et al. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group. Eur J Cancer 2013; 49: 3486 3496.
40. Huang Y-H, Hsiao L-T, Hong Y-C et al. Randomized controlled trial of entecavir prophylaxis for rituximab-Associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013; 31: 2765 2772.
41. Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology 2015; 61: 703 711.
42. Kubo A, Shlager L, Marks AR et al. Prevention of vertical transmission of hepatitis B: An observational study. Ann Intern Med 2014; 160: 828 835.
43. Zou H, Chen Y, Duan Z, Zhang H, Pan C. Virologic factors associated with failure to passiveactive immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat 2012; 19: e18 e25.
44. Han G-R, Cao M-K, Zhao W et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 2011; 55: 1215 1221.
45. Pan CQ, Han G-R, Jiang H-X et al. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol 2012; 10: 520 526.
46. Shi Z, Yang Y, Ma L, Li X, Schreiber A. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: A systematic review and meta-Analysis. Obstet Gynecol 2010; 116: 147 159.
47. Xu W-M, Cui Y-T, Wang L et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: A multicentre, randomized, double-blind, placebocontrolled study. J Viral Hepat 2009; 16: 94 103.
48. Celen MK, Mert D, Ay M et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. World J Gastroenterol 2013; 19: 9377 9382.
49. Lacombe K, Rockstroh J. HIV and viral hepatitis coinfections: Advances and challenges. Gut 2012; 61: i47 i58.
50. Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991; 163: 1138 1140.
51. Nikolopoulos GK, Paraskevis D, Hatzitheodorou E et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: A cohort study and meta-Analysis. Clin Infect Dis 2009; 48: 1763 1771.
52. Thio CL, Seaberg EC, Skolasky R et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921 1926.
53. Qurishi N, Kreuzberg C, Luchters G et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet (London, England) 2003; 362: 1708 1713.
54. Brau N, Salvatore M, Rios-Bedoya CF. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44: 47 55.
55. Joshi D, O Grady J, Dieterich D et al. Increasing burden of liver disease in patients with HIV infection. Lancet (London, England) 2011; 377: 1198 1209.
56. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 10 January 2011; pp 1 1Available at: https://aidsinfo.nih.gov/ contentfiles/adultandadolescent.pdf; accessed on 11 March 2015.
57. Liaw Y-F, Leung N, Kao J-H et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update. Hepatol Int 2008; 2: 263 283.
58. Lau GKK, Piratvisuth T, Luo KX et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682 2695.
59. Buster EHCJ, Flink HJ, Cakaloglu Y et al. Sustained HBeAg and HBsAg loss after long-Term follow-up of HBeAg-positive patients treated with peginterferon ?-2b. Gastroenterology 2008; 135: 459 467.
60. Buster EHCJ, Hansen BE, Lau GKK et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-Alfa. Gastroenterology 2009; 137: 2002 2009.
61. Fontana RJ. Side effects of long-Term oral antiviral therapy for hepatitis B. Hepatology 2009; 49: S185 S195.
62. Gara N, Zhao X, Collins MT et al. Renal tubular dysfunction during long-Term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther 2012; 35: 1317 1325.
63. Pipili C, Cholongitas E, Papatheodoridis G. Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease. Aliment Pharmacol Ther 2014; 39: 35 46.
64. Tourret J, Deray G, Isnard-Bagnis C. Tenofovir effect on the kidneys of HIV-infected patients: A double-edged sword? J Am Soc Nephrol 2013; 24: 1519 1527.
65. Gupta SK. Tenofovir-Associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS 2008; 22: 99 103.
66. Manns MP, Akarca US, Chang T-T et al. Long-Term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-9Expert Opin Drug Saf 2012; 11: 361 368.
67. Lange CM, Bojunga J, Hofmann WP et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009; 50: 2001 2006.
68. Chang TT, Lai CL, Yoon S et al. Entecavir treatment for upto 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422 430.
69. Marcellin P, Heathcote EJ, Buti M et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. Engl J Med 2008; 359: 2442 2455.
70. Heathcote EJ, Marcellin P, Buti M et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140: 132 143.
71. Tenney DJ, Rose RE, Baldick CJ et al. Long-Term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years-of therapy. Hepatology 2009; 49: 1503 1514.
72. Snow-Lampart A, Chappell B, Curtis M et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011; 53: 763 773.
73. Terrault NA, Bzowej NH, Chang K-M et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016; 63: 261 283.
74. Wong GL-H, Wong VW-S, Chan HL-Y. Combination therapy of interferon and nucleotide/ nucleoside analogues for chronic hepatitis B. J Viral Hepat 2014; 21: 825 834.
75. Marcellin P, Ahn SH, Ma X et al. Combination of tenofovir disoproxil fumarate and peginterferon ?-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology 2016; 150: 134 144.e10.
76. WHO. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. WHO: Geneva, Switzerland, 2015, p 136.
77. Pan X, Zhang K, Yang X et al. Relapse rate and associated-factor of recurrence after stopping NUCs therapy with different prolonged consolidation therapy in HBeAg positive CHB patients. PLoS One 2013; 8: e68568.
78. Wong GLH, Tse YK, Wong VWS et al. Chan HLY. Long-Term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects. Hepatology 2015; 62: 684 693.
79. Chen C-H, Hung C-H, Hu T-H et al. Association between level of hepatitis B surface antigen and relapse after entecavir therapy for chronic HBV infection. Clin Gastroenterol Hepatol 2015; 13: 1984 1992.e1.
80. Trépo C, Chan HLY, Lok A. Hepatitis B virus infection. Lancet (London, England) 2014; 384: 2053 2063.
81. Mast EE, Weinbaum CM, Fiore AE et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55: 1 33; quiz CE1 CE4.
82. WHO. Immunization Coverage Fact sheet. WHO: Geneva, Switzerland, 20Available at: http://www.who.int/mediacentre/factsheets/fs378/en/ (last accessed 3 November 2016).
83. Kapoor R, Kottilil S. Strategies to eliminate HBV infection. Fut Virol 2014; 9: 565 585.
84. Zeisel MB, Lucifora J, Mason WS et al. Towards an HBV cure: state-of-The-Art and unresolved questions-report of the ANRS workshop on HBV cure. Gut 2015; 64: 1314 1326.
85. Lucifora J, Xia Y, Reisinger F et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014; 343: 1221 1228.
86. Carroll D. Genome engineering with zinc-finger nucleases. Genetics 2011; 188: 773 782.
87. Cai D, Mills C, Yu W et al. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother 2012; 56: 4277 4288.
88. Fosdick A, Zheng J, Pflanz S et al. Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses. J Pharmacol Exp Ther 2014; 348: 96 105.
89. Lanford RE, Guerra B, Chavez D et al. GS-9620, an oral agonist of toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 2013; 144: 1508 1517.
90. Bertoletti A, Gehring A. Therapeutic vaccination and novel strategies to treat chronic HBV infection. Expert Rev Gastroenterol Hepatol 2013; 3: 561 569.
91. Xu D-Z, Zhao K, Guo L-M et al. A randomized controlled phase IIb trial of antigen antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS One 2008; 3: e2565.
92. Yao X, Zheng B, Zhou J et al. Therapeutic effect of hepatitis B surface antigen-Antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients. Vaccine 2007; 25: 1771 1779.
93. Pol S, Michel M-L. Therapeutic vaccination in chronic hepatitis B virus carriers. Expert Rev Vaccines 2006; 5: 707 716.
94. Block TM, Gish R, Guo H et al. Chronic hepatitis B: What should be the goal for new therapies? Antiviral Res 2013; 98: 27 34